Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 11.81
ALXN's Cash to Debt is ranked higher than
70% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ALXN: 11.81 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 11.81

Equity to Asset 0.80
ALXN's Equity to Asset is ranked higher than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.80 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.95
Current: 0.8

0.04
0.95
Interest Coverage 128.41
ALXN's Interest Coverage is ranked higher than
58% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 128.41 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 128.41

14.38
9999.99
F-Score: 6
Z-Score: 30.30
M-Score: -2.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 34.04
ALXN's Operating margin (%) is ranked higher than
96% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ALXN: 34.04 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 35.65
Current: 34.04

-10370.21
35.65
Net-margin (%) 16.30
ALXN's Net-margin (%) is ranked higher than
91% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ALXN: 16.30 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 16.3

-10220.86
76.31
ROE (%) 10.62
ALXN's ROE (%) is ranked higher than
90% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. ALXN: 10.62 )
ALXN' s 10-Year ROE (%) Range
Min: -160.7   Max: 42.88
Current: 10.62

-160.7
42.88
ROA (%) 7.62
ALXN's ROA (%) is ranked higher than
91% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ALXN: 7.62 )
ALXN' s 10-Year ROA (%) Range
Min: -43.83   Max: 37.53
Current: 7.62

-43.83
37.53
ROC (Joel Greenblatt) (%) 155.90
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. ALXN: 155.90 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -955.65   Max: 155.9
Current: 155.9

-955.65
155.9
Revenue Growth (%) 38.70
ALXN's Revenue Growth (%) is ranked higher than
94% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ALXN: 38.70 )
ALXN' s 10-Year Revenue Growth (%) Range
Min: -70.5   Max: 498.1
Current: 38.7

-70.5
498.1
EBITDA Growth (%) 46.50
ALXN's EBITDA Growth (%) is ranked higher than
98% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ALXN: 46.50 )
ALXN' s 10-Year EBITDA Growth (%) Range
Min: -10.1   Max: 72.8
Current: 46.5

-10.1
72.8
EPS Growth (%) 34.70
ALXN's EPS Growth (%) is ranked higher than
96% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ALXN: 34.70 )
ALXN' s 10-Year EPS Growth (%) Range
Min: -15.3   Max: 77.3
Current: 34.7

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ALXN Guru Trades in Q2 2013

Steven Cohen 89,400 sh (+1137.03%)
Jeremy Grantham 69,727 sh (+0.99%)
Frank Sands 8,424,567 sh (+0.05%)
Jim Simons Sold Out
Paul Tudor Jones 3,800 sh (-32.14%)
Andreas Halvorsen 5,544,949 sh (-41.4%)
Pioneer Investments 30,500 sh (-81.06%)
» More
Q3 2013

ALXN Guru Trades in Q3 2013

Eric Mindich 300,000 sh (New)
Pioneer Investments 84,977 sh (+178.61%)
Steven Cohen 201,270 sh (+125.13%)
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Frank Sands 7,540,405 sh (-10.5%)
Andreas Halvorsen 3,454,640 sh (-37.7%)
» More
Q4 2013

ALXN Guru Trades in Q4 2013

Eric Mindich Sold Out
Frank Sands 7,370,601 sh (-2.25%)
Andreas Halvorsen 2,877,008 sh (-16.72%)
Pioneer Investments 30,500 sh (-64.11%)
Steven Cohen 67,536 sh (-66.45%)
» More
Q1 2014

ALXN Guru Trades in Q1 2014

John Burbank 1,318 sh (New)
Paul Tudor Jones 5,725 sh (New)
Ray Dalio 50,371 sh (New)
Joel Greenblatt 5,026 sh (New)
Ron Baron 10,218 sh (New)
Pioneer Investments 31,453 sh (+3.12%)
Frank Sands 5,268,418 sh (-28.52%)
Steven Cohen 45,697 sh (-32.34%)
Andreas Halvorsen 1,836,658 sh (-36.16%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2014-03-31 Reduce -28.52%0.74%$129.82 - $183.89 $ 162.743%5268418
Ray Dalio 2014-03-31 New Buy0.06%$129.82 - $183.89 $ 162.743%50371
John Burbank 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 162.743%1318
Ron Baron 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 162.743%10218
Joel Greenblatt 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 162.743%5026
Frank Sands 2013-09-30 Reduce -10.5%0.27%$94.34 - $117.28 $ 162.7448%7540405
Frank Sands 2013-03-31 Add 4.23%0.11%$83.39 - $102.57 $ 162.7475%8420336
Joel Greenblatt 2013-03-31 Sold Out 0.07%$83.39 - $102.57 $ 162.7475%0
Joel Greenblatt 2012-12-31 New Buy0.07%$87.97 - $118.15 $ 162.7466%12977
Frank Sands 2012-06-30 Add 6.43%0.27%$83.74 - $98.82 $ 162.7479%9739804
George Soros 2012-06-30 Sold Out 0.07%$83.74 - $98.82 $ 162.7479%0
George Soros 2012-03-31 New Buy0.07%$70.29 - $94.31 $ 162.74115%50000
Joel Greenblatt 2011-09-30 Sold Out 0.0882%$47.81 - $66.99 $ 162.74190%0
Joel Greenblatt 2011-06-30 New Buy0.09%$44.61 - $52.195 $ 162.74240%13417
George Soros 2011-06-30 Sold Out $44.61 - $52.195 $ 162.74240%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares
Alexion Pharmaceuticals Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. The company has a market cap of $20.53 billion; its shares were traded at around $105.00 with a P/E ratio of 59.52 and P/S ratio of 15.89. Alexion Pharmaceuticals Inc. had an annual average earnings growth of 70.6% over the past five years. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 99.00
ALXN's P/E(ttm) is ranked higher than
85% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 99.00 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 99

13.92
1113.68
P/B 11.90
ALXN's P/B is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. ALXN: 11.90 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 32.18
Current: 11.9

1.73
32.18
P/S 17.06
ALXN's P/S is ranked higher than
71% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. ALXN: 17.06 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 567.5
Current: 17.06

9.66
567.5
PFCF 86.10
ALXN's PFCF is ranked higher than
90% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 86.10 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 86.1

40
99999999.99
EV-to-EBIT 49.27
ALXN's EV-to-EBIT is ranked higher than
88% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 49.27 )
ALXN' s 10-Year EV-to-EBIT Range
Min: 33   Max: 893.9
Current: 49.27

33
893.9
PEG 1.90
ALXN's PEG is ranked higher than
97% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 1.90 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.63
Current: 1.9

0.68
2.63
Shiller P/E 141.40
ALXN's Shiller P/E is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 141.40 )
ALXN' s 10-Year Shiller P/E Range
Min: 98.32   Max: 655.33
Current: 141.4

98.32
655.33
Current Ratio 5.66
ALXN's Current Ratio is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ALXN: 5.66 )
ALXN' s 10-Year Current Ratio Range
Min: 1.38   Max: 52.92
Current: 5.66

1.38
52.92
Quick Ratio 5.34
ALXN's Quick Ratio is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ALXN: 5.34 )
ALXN' s 10-Year Quick Ratio Range
Min: 1.38   Max: 52.92
Current: 5.34

1.38
52.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.70
ALXN's Price/Net Cash is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. ALXN: 36.70 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 205.55
Current: 36.7

1.37
205.55
Price/Net Current Asset Value 25.50
ALXN's Price/Net Current Asset Value is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. ALXN: 25.50 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.37   Max: 470.75
Current: 25.5

1.37
470.75
Price/Tangible Book 17.50
ALXN's Price/Tangible Book is ranked higher than
62% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. ALXN: 17.50 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.15   Max: 82.09
Current: 17.5

1.15
82.09
Price/DCF (Projected) 6.20
ALXN's Price/DCF (Projected) is ranked higher than
91% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 6.20 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.42   Max: 142.19
Current: 6.2

4.42
142.19
Price/Median PS Value 1.00
ALXN's Price/Median PS Value is ranked higher than
83% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALXN: 1.00 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 45.9
Current: 1

0.34
45.9
Price/Peter Lynch Fair Value 4.00
ALXN's Price/Peter Lynch Fair Value is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 4.00 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 4

0.56
4.22
Price/Graham Number 8.70
ALXN's Price/Graham Number is ranked higher than
86% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 8.70 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.04   Max: 22.85
Current: 8.7

2.04
22.85
Earnings Yield (Greenblatt) 2.00
ALXN's Earnings Yield (Greenblatt) is ranked higher than
53% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. ALXN: 2.00 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 2

0.1
3
Forward Rate of Return (Yacktman) 53.87
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. ALXN: 53.87 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.1   Max: 75.3
Current: 53.87

-7.1
75.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany
Alexion Pharmaceuticals, Inc. is a Delaware based company incorporated in 1992 is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. Soliris is a humanized monoclonal antibody that blocks terminal complement activity at the doses currently prescribed. Soliris was approved for the treatment of PNH by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) in 2007 and by Japan's Ministry of Health, Labour and Welfare (MHLW) in 2010, and has been approved in several other territories. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
fv 107 Apr 01 2013 
Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 
Weekly Top Insider Sells: GOOG, YHOO, ALXN, and CTL Jun 04 2012 
Alexion is Betting on Soliris and a Little Charity Mar 06 2012 


More From Other Websites
Biotech ETF Price Swings May Signal Need For Caution Jul 28 2014
Midday movers: Cummins, Dollar Tree, Zillow & More Jul 28 2014
ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 25 2014
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 24 2014
Celgene, Alexion Beat Estimates, But Biotechs Fall Jul 24 2014
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View Jul 24 2014
Biotechs beat estimates, but the Street wants more Jul 24 2014
Video: Celgene, Alexion Earnings Top, But Stocks Fall Jul 24 2014
Q2 2014 Alexion Pharmaceuticals, Inc. Earnings Release - Before Market Open Jul 24 2014
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a... Jul 24 2014
Alexion Reports Second Quarter 2014 Results Jul 24 2014
Alexion Reports Second Quarter 2014 Results Jul 24 2014
Alexion's hypophosphatasia candidate MAA accepted by European Medicines Agency Jul 24 2014
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a... Jul 24 2014
Will Alexion Pharmaceuticals (ALXN) Miss This Earnings Season? Jul 23 2014
S&P 500 Posts New High; Biotechs, Airlines, Builders Up Jul 23 2014
S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade Jul 23 2014
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 Jul 23 2014
Video: Biogen Trounces Q2 Estimates On Tecfidera Jul 23 2014
Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Unusual Social Activity Stock Jul 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide